Lineage Cell Therapeutics (LCTX) Non-Current Deferred Tax Liability (2017 - 2025)
Lineage Cell Therapeutics (LCTX) has 11 years of Non-Current Deferred Tax Liability data on record, last reported at $273000.0 in Q3 2025.
- For Q3 2025, Non-Current Deferred Tax Liability changed 0.0% year-over-year to $273000.0; the TTM value through Sep 2025 reached $273000.0, changed 0.0%, while the annual FY2024 figure was $273000.0, 0.0% changed from the prior year.
- Non-Current Deferred Tax Liability reached $273000.0 in Q3 2025 per LCTX's latest filing, roughly flat from $273000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $2.1 million in Q1 2021 and bottomed at $273000.0 in Q1 2023.
- Average Non-Current Deferred Tax Liability over 5 years is $899111.1, with a median of $273000.0 recorded in 2023.
- Peak YoY movement for Non-Current Deferred Tax Liability: surged 132.21% in 2022, then crashed 86.85% in 2023.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $894000.0 in 2021, then soared by 132.21% to $2.1 million in 2022, then plummeted by 86.85% to $273000.0 in 2023, then changed by 0.0% to $273000.0 in 2024, then changed by 0.0% to $273000.0 in 2025.
- Per Business Quant database, its latest 3 readings for Non-Current Deferred Tax Liability were $273000.0 in Q3 2025, $273000.0 in Q2 2025, and $273000.0 in Q1 2025.